Items Tagged ‘Verzenio’

October 30, 2017

Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer


Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer progression compared to treatment with fulvestrant alone in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), […]

View full entry

Tags: 4 & 6 inhibitor, abemaciclib, advanced breast cancer, Breast Cancer, CDK, cyclin-dependent kinase, News, Phase 3 MONARCH 2, Precision Cancer Medicine, Verzenio

October 5, 2017

FDA approves new treatment for certain advanced or metastatic breast cancers


The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine […]

View full entry

Tags: abemaciclib, Breast Cancer, fulvestrant, hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, Metastatic Breast Cancer, News, Precision Cancer Medicine, Verzenio